The NIH Public Access Policy. Kristen L. Young, MLIS, AHIP Medical Librarian January 22, 2015

Transcription

1 The NIH Public Access Policy Kristen L. Young, MLIS, AHIP Medical Librarian January 22, 2015

2 The NIH Public Access Policy is Mandatory The Policy implements Division G, Title II, Section 218 of PL (Consolidated Appropriations Act, 2008) which states: The Director of the National Institutes of Health shall require that all investigators funded by the NIH submit or have submitted for them to the National Library of Medicine s PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication: provided, that the NIH shall implement the public access policy in a manner consistent with copyright law. NIH Guide Notice NOT-OD NIH Guide Notice NOT-OD announces the policy is permanent, per the Consolidated Appropriations Act,

3 Importance A grantee s failure to comply with the terms and conditions of award..nih may take proactive actions including placing special conditions on awards or precluding the grantee from obtaining future awards for a specified period, or may take action designed to prevent future non-compliance, such as closer monitoring. policy statement 10/11. With this notice, NIH informs grantees that in Spring, 2013, at the earliest, NIH will delay processing of non-competing continuation grant awards if publications arising from that award are not in compliance with the NIH public access policy. The award will not be processed until recipients have demonstrated compliance.

4 The policy applies to any manuscript that Is peer-reviewed; Is accepted for publication in a journal on or after April 7, 2008; And, arises from: Any direct funding from an NIH grant or cooperative agreement active in Fiscal year 2008-beyond, or: Any direct funding from an NIH contract signed on or after April 7, 2008, or: Any direct funding from an NIH Intramural Program, or: An NIH employee.

5 Difference: Medline & PubMed The Tool MEDLINE Largest component of PubMed Includes references to articles indexed with terms from NLM s controlled vocabulary PubMed Also contains OLDMEDLINE (pre-1950 citations) Contains some out-of-scope materials from MEDLINE In-process citations searchable Some life science and physics journals Links to full-text Single citation matcher Clinical queries Spell checker Other filters One of the ways to drive the Tool! E.G. Detlefsen

6 PubMed vs PubMed Central (PMC) Free resources developed by the U.S. National Library of Medicine PMID: VS PMC: Biomedical journal citations + abstracts Some links to full text articles at PMC and publisher sites Unique identifier: PMID followed by a series of numbers Digital archive of full-text, peerreviewed journal papers Unique identifier: PMCID followed by a series of numbers

7 PubMed vs PubMed Central (PMC) VS is analogous to VS

8 PubMed Central (PMC)

9 Address Copyright Institutions and investigators are responsible for ensuring full compliance with the Public Access Policy. Make sure the copyright transfer agreement allows the final peer-reviewed manuscript to be submitted to NIH. Encourage all authors to consider Who will submit the paper and/or approve the submission? What version of the paper will be made available on PMC? When will it be submitted and when will the paper be made public on PMC?

10 Posting Papers The 4 ways papers make their way into PMC: Method A: Publish in a PMC participating journal. Method B: Arrange to have a publisher deposit the final published article in PMC. Method C: Submit the final peer-reviewed manuscript to the NIHMS. Method D: A publisher begins the submission process for a manuscript via the NIHMS.

11 Required for NIH Manuscript Submission PI Name and Title of the journal Title of the manuscript Final peer-reviewed version of the manuscript Or final published version if journal allows Supplemental materials or graphics associated with the manuscript Grant number/s All information as necessary for following the stipulations set forth by some journal publishers, including the embargo period

12 Preparation is key to avoiding delays in funding Do you have a plan that can withstand Miscommunication among authors, and between publishers and authors? Forgetfulness? Encourage your investigators to: Use My NCBI now to track public access compliance Associate papers with awards today Ensure compliance well before their annual reports are due, to avoid a last minute scramble Determine their compliance plan as they write their papers

13 Ways institutions can ensure compliance Training Policy awareness, submitting papers, preparing citations Author support Submitting manuscripts Answering questions Sending out reminders for repots early Means to ensure collaborators do not prevent compliance Support on publishing agreements Policies Coversheets/Agenda Questions/discussion with publishers Ensuring compliance Checking applications, proposals and reports

14 Resources About the Public Access Policy For Sponsored Programs Training materials for PIs and other communications Questions The NIH Manuscript Submission System Tutorials PubMed Central

15 Images & ClinicalKey

16 Visit: hsl.howard.edu

17 Resource Login

18 ClinicalKey:add an image to your presentation

19 ClinicalKey:add an image to your presentation

20 ClinicalKey:add an image to your presentation

21 Exporting images to your presentation

22 Similarities between reactive gastric cardiac mucosa (A, B) and dysplastic Barrett's mucosa (C) may lead not only to the overdiagnosis of Barrett's esophagus itself but also to the diagnosis of dysplastic Barrett's mucosa. The similarities include mucin loss and sometimes marked nuclear atypia, as seen in A (at higher magnification) and B. The differences include the often more bland gastric mucinous glands at the base of the mucosa (B) relative to the more atypical surface ( A, black arrow ) (so-called top-heavy atypia of reactive gastric mucosa) in comparison to the opposite pattern in Barrett's esophagus, when the atypia is characteristically most severe in the deep glands (C) (so-called bottom-heavy atypia). Mitotic figures may also be helpful, because the mitotic or regenerative zone of gastric mucosa resides in the central or neck region of the gastric crypt ( A, white arrowhead ), whereas in Barrett's esophagus and in any intestinal-type epithelium the regenerative zone emanates from the deepest part of the crypt. The locations of the regenerative zones (neck or mid mucosa in gastric and deep in intestinal) explains the top - or bottom -heavy patterns of atypia characteristic of these two different epithelia. Finally, reactive gastric foveolar cells commonly retain a well-developed linear array of small apical foveolar mucin caps along the mucosal surface ( A, black arrow ), which is not as common in dysplastic Barrett's epithelium. (Hematoxylin and eosin.) HISTOPATHOLOGY OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT'S ESOPHAGUS

23 AccessMedicine

24

25 From: Gastrointestinal Tract CURRENT Diagnosis & Treatment: Pediatrics, 22e, 2013 Legend: Esophagitis associated with gastroesophageal reflux disease. Mucosa is erythematous with loss of vascular pattern. Date of download: 1/15/2015 Copyright 2015 McGraw-Hill Education. All rights reserved.

26 Adding an image to an existing PowerPoint

27 Add images to an existing PowerPoint

28 Thank you!

29 Publicaccess.nih.gov

30 NIH Manuscript Submission System